Trials / Available
AvailableNCT06415448
Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema
Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema (HAE)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of the Expanded Access Program is to provide pre-approval access of donidalorsen to eligible patients with Hereditary Angioedema (HAE) who complete the ISIS 721744-CS3 clinical trial.
Detailed description
The Expanded Access Program (EAP) is intended to provide pre-approval access to donidalorsen for eligible patients with HAE who complete the ISIS 721744-CS3 clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donidalorsen | Donidalorsen administered once monthly or every other month by subcutaneous (SC) injections in the abdomen, thigh, or upper arm. |
Timeline
- First posted
- 2024-05-16
- Last updated
- 2025-07-11
Source: ClinicalTrials.gov record NCT06415448. Inclusion in this directory is not an endorsement.